Frontlight ResearchEarly access
TerminatedNo phase
SHARPEN - Parkinson's Disease Dementia
Key facts
- Who runs it
- Scion NeuroStim
- Where
- Boca Raton and Kansas City, United StatesSee the 2 sites
- Trial code
- Status
- Terminated
- People taking part
- 9 people enrolled
- Started
- 8 May 2024
- Ended
- 24 Feb 2025
- Type of study
- Interventional
- Treatments tested
- Non-invasive brainstem stimulation
- Record updated
- 9 May 2025
- Why it stopped
- Company closure
Who can take part
- Age
- 50 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Adults, age 50 years of older, diagnosed with Clinically Established or Clinically Probable Parkinson's disease according to the MDS Clinical Diagnostic Criteria
- Participants with a clinical diagnosis of probable Parkinson's disease dementia ( PDD) using criteria defined in Emre et al., 2007 and in accordance with procedures defined in Dubois et al., 2007 (allowing for diagnosis of PD defined in Step 1 to be according to MDS Clinical Diagnostic criteria instead of the Queen Square Brain Bank Criteria)
- Participants must be able and willing to consent to participate in the study and comply with all study requirements. If the participant is unable to consent due to limited capacity, a Legally Authorized Representative (LAR) must consent
- Participants and investigators must expect that the participant will be able to remain on a stable regimen of concomitant therapies used for the management of PD and not to introduce new medications used to treat PD (motor or non-motor symptoms) during the study
- The principal investigator, or designee, must have confidence in the participant's ability to reliably use the TNM™ device, and to understand and complete the assessments (provided in English only) within a given on-state
- Participant must have a study partner (defined as someone who sees the participant for more than three hours a day, 5 times per week) that is willing to consent and participate in the trial
Who cannot take part
- Are receiving late-stage therapies for PD (e.g., deep brain stimulation or pump infusion therapies) or are being treated with another neurostimulation device
- History of interventional brain surgery or have received magnetic resonance guided high intensity focused ultrasound
- Have been previously diagnosed with either clinically meaningful central vestibular dysfunction (lifetime) or have experienced clinically meaningful peripheral vestibular dysfunction within the last 12 months
- Use any drugs excluded in the Excluded Medications List
- Have a cochlear implant, myringotomy tubes or hearing aids that cannot be easily/reliably removed for treatment
- Has any significant co-morbidity/condition, planned surgery or participation in another clinical trial which may either prevent safe participation in the study procedures or interfere with the evaluation of safety or efficacy of the study Device as a potential treatment for PDD
- In the Investigator's opinion, has severe dementia, (e.g., Mini Mental State Exam score (at screen visit) <15 and/or requires significant assistance with activities of daily living due to cognitive deficits)
- Has experienced a myocardial infarction, angina, or stroke within the past 12 months, transient ischemic attack (TIA) within the past 6 months or has a documented aspiration event in the medical records
- Have active ear infections, perforated tympanic membrane or labyrinthitis, as identified by a general ear examination
- Have active ear infections, perforated tympanic membrane or labyrinthitis, as identified by a general ear examination performed by medically qualified Investigators or have chronic tinnitus that has been ongoing for at least 3 months
- Use of antipsychotic medication(s) listed in the Approved Concomitant Medications (i.e., pimavanserin and quetiapine) that have not been taken for more than 180 days and does not have medical record documentation of normal QTc interval (i.e., no prolongation of the QTc interval) as measured via electrocardiogram after starting the medication
- Clinically significant abnormalities in B12, thyroid function, blood count, comprehensive metabolic panel or urinalysis results tested at the study screen. Screening tests are not required in cases where test results within normal range within 6 months of study screen are documented in the medical records
- Participant anticipates being unable to attend all visits and complete all study activities during the trial
- Women of child-bearing potential who are pregnant or plan to become pregnant during the course of the trial
- Demonstrate suicidality at screening (scores ≥ 4 on the Columbia- Suicide Severity Rating Scale Baseline "In the past Month" section)
Where in United States
- Parkinson's Disease and Movement Disorder Center of Boca RatonBoca Raton, United States
- University of Kansas Medical Center - Parkinson's Disease CenterKansas City, United States
About the trial
What the trial wants to find out
The purpose of this single arm study is to evaluate the feasibility and safety of treatments with a non-invasive neuromodulation device in adults diagnosed with mild/moderate Parkinson's disease dementia (PDD). A non-invasive device is a device that stays outside of the body and is not implanted and does not penetrate the skin.
Read full original descriptionShow less
Neuromodulation means that the device stimulates activity in the brain.
The group in the trial
- Investigational TreatmentTreatment being tested
Time-varying caloric vestibular stimulation
Treatment: Non-invasive brainstem stimulation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Simple, Home-use Neurostimulation tReatment for Parkinson's Disease dEmeNtia
- Record updated
- 9 May 2025